AUTOLUS
Autolus is in T-cell programming and manufacturing technology and believes its leadership will provide a competitive advantage as it looks to develop future generations of T cell therapies targeting both hematological cancers and solid tumors. It is engaged in the development of next-generation programmed T cell therapies for the treatment of cancer. The company's pipeline includes AUTO1, AUTO2, AUTO3, AUTO4, and others.
AUTOLUS
Social Links:
Industry:
Biopharma Biotechnology Medical Pharmaceutical
Founded:
2014-01-01
Address:
London, England, United Kingdom
Country:
United Kingdom
Website Url:
http://www.autolus.com
Total Employee:
101+
Status:
Active
Contact:
+44 (0)20 3829 6230
Email Addresses:
[email protected]
Total Funding:
631.71 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon Microsoft Exchange Online Microsoft Azure DNS ASP.NET IIS ASP.NET 4.0
Similar Organizations
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Versameb
Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs.
Current Employees Featured
Founder
Stock Details
Investors List
Blackstone Group
Blackstone Group investment in Post-IPO Equity - Autolus
PPF Group
PPF Group investment in Post-IPO Equity - Autolus
4BIO Capital
4BIO Capital investment in Post-IPO Equity - Autolus
Syncona Partners LLP
Syncona Partners LLP investment in Series C - Autolus
UCLB
UCLB investment in Series C - Autolus
Nextech Invest
Nextech Invest investment in Series C - Autolus
Cormorant Asset Management
Cormorant Asset Management investment in Series C - Autolus
GV
GV investment in Series C - Autolus
Arix Bioscience
Arix Bioscience investment in Series C - Autolus
Woodford Investment Management
Woodford Investment Management investment in Series C - Autolus
Official Site Inspections
http://www.autolus.com Semrush global rank: 1.09 M Semrush visits lastest month: 29.98 K
- Host name: 13.69.68.48
- IP address: 13.69.68.48
- Location: Amsterdam Netherlands
- Latitude: 52.3534
- Longitude: 4.9087
- Timezone: Europe/Amsterdam
- Postal: 1091
More informations about "Autolus" on Search Engine
Autolus - developing CAR T cell therapies for cancer patients
Autolus is a CAR T cell therapy company which develops advanced autologous T cell therapies that have the potential to deliver life-changing benefits to cancer patients.See details»
Our purpose | About us | Autolus
Autolus is a leader in T cell programming, underpinning the broad technology toolbox and manufacturing technology. Autolus is developing cancer therapies which we believe will offer patients substantial benefits over the existing standard of care.See details»
Autolus - Crunchbase Company Profile & Funding
Autolus is a biopharmaceutical company focused on T-cell programming and manufacturing technology. London, England, United Kingdom. 251-500. Post-IPO Equity. Public. www.autolus.com. 554. Highlights. Stock Symbol NASDAQ:AUTL. Total Funding Amount. Unlock for free. Contacts 158. Employee Profiles 9. Investors 10. Similar …See details»
Autolus Therapeutics | LinkedIn
Autolus Therapeutics | 22,191 followers on LinkedIn. Focused on the development of precisely targeted, controlled & highly active T cell therapies for cancer | Autolus is a clinical-stage ...See details»
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy ...
February 8, 2024 at 5:45 AM EST. PDF Version. Strategic alliance leverages manufacturing and commercial infrastructure as well as technology with the aim to advance both companies’ autologous CAR-T programs towards market, pending market authorization. BioNTech secures the right to utilize Autolus’ manufacturing capacity in a cost-efficient ...See details»
Innovation | Autolus
July 06 2023. Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia. We apply our broad array of T cell programing technologies and capabilities to engineer precisely targeted controlled and highly active T cell therapies.See details»
Healthcare Professionals | Autolus
Autolus actively collaborates with healthcare professionals and various essential stakeholders to deliver gene therapies to patients. We are dedicated to engaging with individuals and organizations involved in the specific disease areas we focus on, and we continuously seek out new partnerships.See details»
News | Investor relations | Autolus
Mar 11, 2024 Autolus Therapeutics Announces Changes to its Board of Directors. Mar 14, 2024. Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates. Mar 12, 2024. Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site. Mar …See details»
Pipeline products | Innovation | Autolus
Alongside obe-cel, Autolus is progressing a number of pipeline assets both in preclinical and clinical development across hematological malignancies and solid tumors. Our pipeline Obe-celSee details»
Our products | Pipeline products | Innovation | Autolus
Designer Small-Molecule Control System Based on Minocycline-Induced Disruption of Protein–Protein Interaction. Control. Autolus is applying our extensive cell programing capability develop product candidates across hematological malignancies and solid tumors.See details»
Investor Relations | Autolus Therapeutics plc
Apr 2, 2024 Corporate Profile. Autolus is a clinical-stage, biopharmaceutical company, focused on the development and commercialisation of engineered T-cell immunotherapy products to combat cancer.See details»
Autolus Therapeutics: The Story Has Improved (NASDAQ:AUTL)
Feb 14, 2023 Autolus Therapeutics is an early stage developmental company. The company is headquartered in London and is focused on developing T cell therapies for the treatment of cancer. It has several...See details»
Autolus - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Autolus. Connect to CRM. Summary Financials People Technology Signals & News Similar Companies. Highlights. Employee Profiles 9. Contacts 158. About. Autolus has 9 current employee profiles, including Chief Executive Officer Christian Itin. Contacts. Job Department. General Counsel. Non-Management , Executive Legal , Management.See details»
Autolus Therapeutics Could Hold A Winning CAR T-Cell Ticket
Jun 30, 2023 Healthcare. Autolus Therapeutics Could Hold A Winning CAR T-Cell Ticket. Jun. 30, 2023 7:34 PM ET Autolus Therapeutics plc (AUTL) Stock 2 Comments. 3 Likes. Clinically Sound Investor. 3.99K...See details»
Autolus - Funding, Financials, Valuation & Investors - Crunchbase
Autolus has raised a total of. $1.1B. in funding over 10 rounds. Their latest funding was raised on Feb 8, 2024 from a Post-IPO Equity round. Autolus is registered under the ticker NASDAQ:AUTL . Their stock opened with $17.00 in its Jun 22, 2018 IPO. Autolus is funded by 10 investors. Blackstone Group and PPF Group are the most recent investors ...See details»
Autolus Therapeutics Submits Biologics License Application to …
LONDON, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today...See details»
Autolus Therapeutics announces retirement of chief
LONDON, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced...See details»
Autolus Therapeutics announces acceptance of Biologics License ...
LONDON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today...See details»